Transfusion Medicine Reviews
Volume 17, Issue 2 , Pages 120-162 , April 2003

Risks associated with transfusion of cellular blood components in canada

References 

  1. Linden JV, Kaplan HS. Transfusion errors: Causes and effects. Trans Med Rev. 1994;8:169–183
  2. Busch MP, Watanabe KK, Smith JW, et al. , for the Retrovirus Epidemiology Donor Study   False-negative testing errors in routine viral marker screening of blood donors. Transfusion. 2000;40:585–589
  3. Robillard P, Karl Itaj N. Incidence of adverse transfusion reactions in the Quebec Hemovigilance System. Vox Sang. 2002;83:120; (abstr, suppl)
  4. Agence française du sang . Rapport sur l'activité de transfusion sanguine. Juillet 1994-Juillet 1995. Paris: La Documentation française,; 1996;
  5. Agence française du sang . Rapport sur l'activité de transfusion sanguine. Juillet 1995-Juillet 1996. Paris: La Documentation française,; 1997;
  6. Agence française du sang . Rapport sur l'activité de transfusion sanguine. Août 1996-Décembre 1997. Paris: La Documentation française,; 1998;
  7. David B. Haemovigilance: A comparison of three national systems. In: 27th Congress of the International Society of Blood Transfusion. Vancouver. August 24-29, 2002;
  8. Williamson LM, Lowe S, Love E, et al.  Serious Hazards of Transfusion Annual Report 1997-1998. Manchester, England 1999;
  9. Love EM, Williamson LM, Cohen H, et al.  Serious Hazards of Transfusion Annual Report 1998-1999. Manchester, England 2000;
  10. Love EM, Jones H, Williamson LM, et al.  Serious Hazards of Transfusion Annual Report 1999-2000. Manchester, England 2001;
  11. Asher D, Atterbury CLJ, Chapman C, et al.  Serious Hazards of Transfusion Annual Report 2000-2001. Manchester, England 2002;
  12. Centers for Disease Control and Prevention and World Health Organization . EPI-INFO Software. Version 6.04. 1998;
  13. Vamvakas EC, Taswell HF. Long-term survival after blood transfusion. Transfusion. 1994;34:471–477
  14. Tynell E, Norda R, Shanwell A, et al.  Long term survival in transfusion recipients in Sweden, 1993. Transfusion. 2001;41:251–255
  15. Vamvakas EC. Long-term survival of transfusion recipients in Sweden. Transfusion. 2001;41:1173–1176
  16. Kleinman S. Transfusion safety when you don't know what you are looking for: issues related to emerging pathogens. In:  Stramer S editors. Blood Safety in the New Millenium. Bethesda, MD: American Association of Blood Banks; 2001;p. 79–96
  17. Busch MP. Closing the windows on viral transmission by blood transfusion. In:  Stramer S editors. Blood Safety in the New Millenium. Bethesda, MD: American Association of Blood Banks; 2001;p. 33–54
  18. Kleinman SH, Busch MP. Risks of transfusion transmitted infection: direct estimation and mathematical modeling. Bailliere's Best Pract Res Clin Haematol. 2000;13:631–649
  19. Kleinman SH, Busch MP, Korelitz JJ, et al.  The incidence/window period model and its use to assess the risk of transfusion-transmitted HIV and HCV infection. Trans Med Rev. 1997;11:155–172
  20. Glynn SA, Kleinman SH, Wright DJ, et al.  International application of the Incidence Rate/Window-Period model. Transfusion. 2002;42:966–972
  21. Donegan E, Stuart M, Niland JC, et al.  Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med. 1990;113:733–739
  22. Alter HJ, Purcell RH, Shih JW, et al.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989;321:1494–1500
  23. Remis RS, Delage G, Palmer RW. Risk of HIV infection from blood transfusion in Montreal. CMAJ. 1997;157:375–382
  24. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross donor population. Transfusion. 2002;42:975–979
  25. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in HCV infection: A perspective on long-term outcome. Semin Liver Dis. 2000;20:17–35
  26. Busch MP. Insights into the epidemiology, natural history, and pathogenesis of hepatitis C infection from studies of infected donors and blood-product recipients. Trans Clin Biol. 2001;8:200–206
  27. Kleinman SH, Busch M. Hepatitis B virus amplified and back in the blood safety spotlight. Transfusion. 2001;41:1081–1085
  28. Korelitz JJ, Busch MP, Kleinman SH, et al.  A method for estimating hepatitis B virus incidence rates in volunteer blood donors. Transfusion. 1997;37:634–640
  29. Kleinman SH, Kuhns MC, Todd DS, et al.  Frequency of HBV DNA detection in US blood donors positive for anti-HBC: Implications for transfusion transmission and donor screening. Transfusion. 2003; (in press)
  30. Allain JP, Hewitt PE, Tedder RS, et al.  Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haem. 1999;107:186–195
  31. Conjeevaram HS, Lok AS. Occult Hepatitis B virus infection: A hidden menace?. Hepatology. 2001;34:204–206
  32. Donegan E, Lee H, Operskalski E, et al.  Transfusion transmission of retroviruses: Human T-lymphotropic viruses types I and II compared with human immunodeficiency virus type 1. Transfusion. 1994;34:478–483
  33. Pennington J, Taylor GP, Sutherland J, et al.  Persistence of HTLV-I in blood components after leukocyte depletion. Blood. 2002;100:677–681
  34. Schreiber GB, Busch MP, Kleinman SH, et al.  The risk of transfusion-transmitted viral infections. N Engl J Med. 1996;334:1685–1690
  35. Chambers RW, Foley HT, Schmidt PJ. Transmission of syphilis by fresh blood components. Transfusion. 1969;9:32–34
  36. Risseeuw-Appel IM, Kothe FC. Transfusion syphilis: A case report. Sex Trans Dis. 1983;10:200–201
  37. Brower WA, Nainan OV, Han X, et al.  Duration of viremia in Hepatitis A Virus infection. J Infect Dis. 2000;182:12–17
  38. Dodd RY. Adverse consequences of blood transfusion: Quantitative risk estimates. In:  Nance ST editors. Blood Supply Risks, Perceptions and Prospects for the Future. Bethesda, MD: American Association of Blood Banks; 1994;p. 1–24
  39. Alter HJ, Bradley DW. Non-A, Non-B hepatitis unrelated to hepatitis C virus (non-ABC). Semin Liver Disease. 1995;15:110–120
  40. Blajchman MA, Bull SB, Feinman V, for the Canadian Post-Transfusion Hepatitis Prevention Study Group . Post-transfusion hepatitis: Impact of non-A, non-B surrogate tests. Lancet. 1995;345:21–25
  41. Allain JP. Emerging viral infections relevant to transfusion medicine. Blood Rev. 2000;14:173–181
  42. Kleinman S. A review of HGV biology, epidemiology, and clinical manifestations with emphasis on implications for blood safety. Trans Med Rev. 2001;15:201–212
  43. Giulivi A, Slinger R, Tepper M, et al.  Prevalence of GBV-C/hepatitis G viremia and anti-E2 in Canadian blood donors. Vox Sang. 2000;79:201–205
  44. Huang LY, Jonassen TO, Hungnes O, et al.  High prevalence of TT virus-related DNA (90%) and diverse viral genotypes in Norwegian blood donors. J Med Virol. 2001;64:381–386
  45. Umemura T, Yeo AE, Sottini A, et al.  SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology. 2001;33:1303–1311
  46. Shibata M, Wang R, Yoshiba M, et al.  The presence of a newly identified infectious agent (SEN Virus) in patients with liver disease and blood donors in Japan. J Infect Dis. 2001;184:400–404
  47. Laupacis A, Brown J, Costello B, et al.  Prevention of posttransfusion CMV in the era of universal leukoreduction: A consensus statement. Transfusion. 2001;41:560–569
  48. Preiksaitis JK. The cytomegalovirus “safe” blood product: is leukoreduction equivalent to antibody screening?. Trans Med Rev. 2000;14:112–136
  49. Reesink HW, Engelfriet CP. International forum: Prevention of post-transfusion cytomegalovirus: Leukoreduction or screening?. Vox Sang. 2002;83:72–73
  50. Bowden RA, Slichter SJ, Sayers M, et al.  A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transplant-associated CMV infection after marrow transplant. Blood. 1995;86:3598–3603
  51. Tegtmeier G. International forum: Prevention of post-transfusion cytomegalovirus: Leukoreduction or screening?. Vox Sang. 2002;83:73–75
  52. Blajchman MA, Goldman M, Freedman JJ, et al.  Proceedings of a consensus conference: Prevention of post-transfusion CMV in the era of universal leukoreduction. Trans Med Rev. 2001;15:1–20
  53. Operskalski EA, Busch MP, Mosley JW, et al.  Blood donations and viruses. Lancet. 1997;349:1327
  54. Todd DS, Pellett PE, Watanabe KK, et al.  Seroprevalence of human herpesvirus 8 (HHV-8) in US blood donors using multiple serologic and PCR assays. Transfusion. 2000;40:97S; (abstr, suppl)
  55. Jordan J, Tiangco C, Kiss J, et al.  Human Parvovirus B19: Prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 1998;75:97–102
  56. McOmish F, Yap PL, Jordan A, et al.  Detection of Parvovirus B19 in donated blood: A model system for screening by polymerase chain reaction. J Clin Micro. 1993;31:323–328
  57. Azzi A, Morfini M, Manucci M. The transfusion-associated transmission of Parvovirus B19. Trans Med Rev. 1999;13:194–204
  58. Mungai M, Tegtmeier G, Chamberland , et al.  Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001;344:1973–1978
  59. Guerrero IC, Weniger BC, Schultz MG. Transfusion malaria in the United States, 1972-1981. Ann Intern Med. 1983;99:221–226
  60. Centers for Disease Control and Prevention . Transfusion-transmitted malaria—Missouri and Pennsylvania. MMWR. 1999;48:253–256
  61. Slinger R, Giulivi A, Bodie-Collins M, et al.  Transfusion-transmitted malaria in Canada. Can Med Assoc J. 2001;164:377–379
  62. Leiby DA. Parasites and other emergent infectious agents. In:  Stramer S editors. Blood Safety in the New Millenium. Bethesda, MD: American Association of Blood Banks; 2001;p. 55–78
  63. McQuiston JH, Childs JE, Chamberland ME, et al.  Transmission of tick-borne agents of disease by blood transfusion: A review of known and potential risks in the United States. Transfusion. 2000;40:274–284
  64. Linden JF, Wong SJ, Chu FK, et al.  Transfusion-associated transmission of babesiosis in New York State. Transfusion. 2000;40:285–289
  65. Jassoum SB, Fong IW, Hannach B, et al.  Transfusion-transmitted babesiosis in Ontario: First reported case in Canada. Can Commun Dis Rep. 2000;26:9–13
  66. Halkier-Sorensen L, Kragballe K, Nedergaard St, et al.  Lack of transmission of Borrelia burgdorferi by blood transfusion. Lancet. 1990;1:550; (letter)
  67. Gerber MA, Shapiro ED, Krause PJ, et al.  The risk of acquiring Lyme disease or babesiosis from a blood transfusion. J Infect Dis. 1994;170:231–234
  68. Eastland T, Persing D, Mathiesen D, et al.  Human granulocytic erhlichiosis after red cell transfusion. Transfusion. 1999;39:117S; (abstr, suppl)
  69. Nickerson P, Orr P, Schroeder ML, et al.  Transfusion-associated Trypanasoma cruzi infection in a non-endemic area. Ann Intern Med. 1989;111:851–853
  70. Lane DJ, Sher G, Ward B, et al.  Investigation of the second case of transfusion-transmitted Chagas disease in Canada. Blood. 2000;96:61a; (abstr)
  71. Leiby DA, Lenes BA, Tibbals MA, et al.  Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion. N Engl J Med. 1999;341:1237–1239
  72. Holman RC, Khan AS, Belay ED, et al.  Creutzfeldt-Jacob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis. 1996;2:333–337
  73. Evatt B, Austin H, Barnhart E, et al.  Surveillance for Creutzfeldt-Jacob disease among persons with hemophilia. Transfusion. 1998;38:817–820
  74. Dodd RY, Sullivan MT. Creutzfeldt-Jacob disease and transfusion-safety: tilting at icebergs?. Transfusion. 1998;38:221–223
  75. Brown P, Cervenekova L, Diringer H. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jacob disease. J Lab Clin Med. 2001;137:5–13
  76. Drohan WN, Cervenekova L. Safety of blood products: are transmissible spongiform encephalopathies (prion diseases) a risk?. Thromb Haem. 1999;82:486–493
  77. WHO . Weekly epidemiological record. December 14, 2001;76:398–400 Available at http://www.who.int/wer Accessed February 1, 2002
  78. UK government Department of Health Web site on CJD/BSE. Available at http://www.doh.gov.uk/cjdSeptember 1, 2002; Accessed
  79. Turner ML, Ludlam CA. Variant Creutzfeldt-Jacob Disease. Trans Med Rev. 2000;14:216–222
  80. Goldman M, Blajchman M. Bacterial Contamination. In: ed 2.  Popovsky M editors. Transfusion Reactions. Bethesda, MD: AABB Press; 2001;p. 129–154
  81. Ness P, Braine H, King K, et al.  Single-donor platelets reduce the risk of septic platelet transfusions. Transfusion. 2001;41:857–861
  82. Yomtovian R, Lazarus HM, Goodnough LT, et al.  A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion. 1993;33:902–909
  83. Yomtovian R. Managing the problem of septic reactions in the hospital environment. 2000 AABB Corporate evening program: Bacterial Contamination of Blood Components. Washington DC November 6, 2000;
  84. Chiu EKW, Yuen KY, Lie AKW, et al.  A prospective study on symptomatic bacteremia from platelet transfusion and its management. Transfusion. 1994;34:950–954
  85. Perez P, Salmi R, Follea G, et al.  Determinants of transfusion-associated bacterial contamination: Results of the French Bacthem Case-control study. Transfusion. 2001;41:862–872
  86. Kuehnert M, Roth VR, Haley NR, et al.  Transfusion-transmitted bacterial infection in the United States, 1998-2000. Transfusion. 2001;41:1493–1499
  87. Robillard P, Karl Itaj N. Bacterial contaminations in the Quebec Hemovigilance system—Year 2000. Vox Sang. 2002;83:16; (suppl, abstr)
  88. Barrett BB, Anderson JW, Anderson KC. Strategies for the avoidance of bacterial contamination of blood components. Transfusion. 1993;33:228–233
  89. Dzieczkowski JS, Barrett BB, Nester D, et al.  Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. Transfusion. 1995;35:20–25
  90. Theakston EP, Morris AJ, Streat SJ, et al.  Transfusion-transmitted Yersinia enterocolitica infection in New Zealand. Aust N Z J Med. 1997;127:62–67
  91. U.S. Department of Health and Human Services . Red blood cell transfusions contaminated with Yersinia enterocolitica—United States, 1991-1996, and initiation of a national study to detect bacteria-associated transfusion reactions. MMWR. 1997;46:553–555
  92. Davenport RD. Hemolytic Transfusion reactions. In: ed 2.  Popovsky M editors. Transfusion Reactions. Bethesda, MD: AABB Press; 2001;p. 1–44
  93. Pineda AA, Brzica SM, Taswell HF. Hemolytic transfusion reaction: Recent experience in a large blood bank. Mayo Clin Proc. 1978;53:378–390
  94. Breandan Moore S, Taswell HF, Pineda AA, et al.  Delayed hemolytic transfusion reactions: Evidence of the need for an improved pretransfusion compatibility test. Am J Clin Pathol. 1980;74:94–97
  95. Lichtiger B, Perry-Thornton E. Hemolytic transfusion reactions in oncology patients: Experience in a large cancer center. J Clin Oncol. 1984;2:438–442
  96. Linden JV, Wagner K, Voytovich AE, et al.  Transfusion errors in New York State. Transfusion. 2000;40:1207–1213
  97. Vamvakas EC, Pineda AA, Reisner R, et al.  The differentiation of delayed hemolytic and delayed serologic transfusion reactions: incidence and predictors of hemolysis. Transfusion. 1995;35:26–32
  98. Pineda AA, Vamvakas EC, Gorden LD, et al.  Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions. Transfusion. 1999;39:1097–1103
  99. Ness PM, Shirey RS, Thoman SK, et al.  The differentiation of delayed serologic and delayed hemolytic transfusion reactions: Incidence, long-term serologic findings, and clinical significance. Transfusion. 1990;30:688–693
  100. McManigal S, Sims KL. Intravascular hemolysis secondary to ABO incompatible platelet products. Am J Clin Pathol. 1999;111:202–206
  101. Larsson LG, Welsh VJ, Ladd DJ. Acute intravascular hemolysis secondary to out-of-group platelet transfusion. Transfusion. 2000;40:902–906
  102. Reis MD, Coovadia AS. Transfusion of ABO-incompatible platelets causing severe haemolytic reaction. Clin Lab Haematol. 1989;11:237–240
  103. Heddle NM, Kelton JG. Febrile nonhemolytic transfusion reactions. In: ed 2.  Popovsky M editors. Transfusion Reactions. Bethesda, MD: AABB Press; 2001;p. 45–82
  104. Uhlmann EJ, Isgriggs E, Wallhermfechtel M, et al.  Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion. 2001;41:997–1000
  105. Tanz WS, King KE, Ness PM. Reevaluation of transfusion reaction rates associated with leukocyte-reduced red blood cells. Transfusion. 2001;41:7S; (abstr, suppl)
  106. Heddle NM, Klama LN, Griffith L, et al.  A prospective study to identify risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion. 1993;33:794–797
  107. Federowicz I, Barrett BB, Anderson JW, et al.  Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion. 1996;36:21–28
  108. Anderson NA, Gray S, Copplestone JA, et al.  A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: Corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Trans Med. 1997;7:33–39
  109. Sarkodee-Adoo CB, Kendall JM, Sridhara R, et al.  The relationship between the duration of platelet storage and the development of transfusion reactions. Transfusion. 1998;38:229–235
  110. Kelley DL, Mangini J, Lopez-Plaza I, et al.  The utility of ≤3-day-old whole-blood platelets in reducing the incidence of febrile nonhemolytic transfusion reactions. Transfusion. 2000;40:439–442
  111. Heddle NM, Blajchman MA, Meyer R, et al.  A randomized controlled trial comparing the frequency of acute reactions of plasma removed platelets and pre-storage leukoreduced platelets. Transfusion. 2002;42:556–566
  112. Couban S, Carruthers J, Andreou P, et al.  Platelet transfusions in children: Results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. Transfusion. 2002;42:753–758
  113. Moore SB. Anaphylactic transfusion reactions—A concise review. Irish Med J. 1985;78:54–56
  114. Vamvakas EC, Pineda AA. Allergic and anaphylactic reactions. In: ed 2.  Popovsky M editors. Transfusion Reactions. Bethesda, MD: AABB Press; 2001;p. 83–128
  115. Sandler GS, Mallory D, Malamut D, et al.  IgA anaphylactic transfusion reactions. Trans Med Rev. 1995;9:1–8
  116. Shimada E, Tadokoro K, Watanabe Y, et al.  Anaphylactic reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. Transfusion. 2002;42:766–773
  117. Take H, Tamura J, Sawamura M, et al.  Severe anaphylactic transfusion reaction associated with HLA-incompatible platelets. Br J Haematol. 1993;83:673–674
  118. Kevy SV, Schmidt PJ, McGinniss MH, et al.  Febrile, nonhemolytic transfusion reactions and the limited role of leukoagglutinins in their etiology. Transfusion. 1962;2:7–16
  119. Pineda AA, Taswell HF. Transfusion reactions associated with anti-IgA antibodies: Report of four cases and review of the literature. Transfusion. 1975;15:10–15
  120. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25:573–577
  121. Clarke G, Podlosky L, Petrie L, et al.  Severe respiratory reactions to random donor platelets: an incidence and nested case-control study. Blood. 1994;84:455; (abstr, suppl)
  122. Henderson RA. Acute transfusion reactions. N Z Med J. 1990;103:509–511
  123. Weber JG, Warner MA, Breanndan Moore S. What is the incidence of perioperative transfusion-related acute lung injury?. Anesthesiology. 1995;8:2789
  124. Palfi M, Berg S, Emerudh J, et al.  randomized controlled trial of transfusion-related acute lung injury: Is plasma from multiparous blood donors dangerous?. Transfusion. 2001;41:317–322
  125. Engelfriet CP, Reesink HW. International forum—Transfusion-related acute lung injury (TRALI). Vox Sang. 2001;81:269–283
  126. Kopko PM, Marshall CS, MacKenzie MR, et al.  Transfusion-related acute lung injury: Report of a clinical look-back investigation. JAMA. 2002;287:1968–1971
  127. Popovsky MA, Taswell HF. Circulatory overload: An underdiagnosed consequence of transfusion. Transfusion. 1985;25:469; (abstr)
  128. Audet AM, Andrzejewski C, Popovsky MA. Red blood cell transfusion practices in patients undergoing orthopedic surgery. A multi-institutional analysis. Orthopedics. 1998;21:851–864
  129. Bierbaum BE, Callaghan JJ, Galante JO, et al.  An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999;81A:2–10
  130. McFarland JG. Posttransfusion Purpura. In: ed 2.  Popovsky M editors. Transfusion Reactions. Bethesda, MD: AABB Press; 2001;p. 187–212
  131. Williamson LM, Warwick RM. Transfusion-associated graft-versus-host disease and its prevention. Blood Rev. 1995;9:251–261
  132. Billingham RE. The biology of graft-vs-host reactions. Harvey Lect. 1966/67;62:21–78
  133. Juji T, Takahashi K, Shibata Y, et al.  Posttransfusion graft-vs-host disease in immunocompetent patients after cardiac surgery. N Engl J Med. 1989;321:56
  134. Webb I, Anerson KC. Transfusion-associated graft-vs-host disease. In: ed 2.  Popovsky MA editors. Transfusion Reactions. Bethesda, MD: AABB Press; 2001;p. 171–186
  135. Ohto H, Yasuda H, Noguchi M, et al.  Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives. Transfusion. 1992;32:691–693
  136. Hume HA, Preiksaitis JB. Transfusion associated graft-versus-host disease, cytomegalovirus infection and HLA alloimmunization in neonatal and pediatric patients. Trans Sci. 1999;21:73–95
  137. Wagner FF, Flegel WA. Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion. 1995;35:284–291
  138. Yasuura K, Okamoto H, Matsuura A. Transfusion-associated graft-versus-host disease with transfusion practice in cardiac surgery. J Cardiovasc Surg. 2000;41:377–380
  139. Roshansky S, Badonnel MC, Hiestand LL, et al.  Transfusion-associated graft-versus-host disease in an immunocompetent patient following cardiac surgery. Vox Sang. 1999;76:59–63
  140. Podlosky L, Morrison D, Van Aerde J, et al.  Transfusion associated graft versus host disease (TA-GVHD) in pediatric practice: Two cases. Trans Med. 2000;3:233; (abstr)
  141. Luban NL, DePalma L. Transfusion-associated graft-versus-host disease in the neonate-expanding the spectrum of disease. Transfusion. 1996;36:101–103
  142. Chang H, Voralia M, Bali M, et al.  Irreversible loss of donor blood leucocyte activation may explain a paucity of transfusion-associated graft-versus-host disease from stored blood. Br J Haematol. 2000;111:146–156
  143. Mincheff M. Changes in donor leukocytes during blood storage. Implications on post-transfusion immunomodulation and transfusion-associated GVHD. Vox Sang. 1998;74:189–200
  144. Akahoshi M, Takanashi M, Masuda M, et al.  A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. Transfusion. 1992;32:169–172
  145. Hayashi H, Nishiuchi T, Tamara H, et al.  Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood. Anesthesiology. 1993;79:1419–1421
  146. United States General Accounting Office . Blood Supply: Transfusion-Associated risks. Washington: US Government Printing Office; 1997;
  147. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion. 1990;30:583–590
  148. Liu HW, Yuen KY, Cheng TS, et al.  Reduction of platelet transfusion-associated sepsis by short-term bacterial culture. Vox Sang. 1999;77:1–5
  149. Dodd RY. Pathogen inactivation for cellular blood components. In:  AuBuchon JP,  Petz L,  Fink A editor. Policy Alternatives in Transfusion Medicine. Bethesda, MD: AABB Press; 2001;
  150. Hill SE. Oxygen therapeutics—Current concepts. Can J Anesth. 2001;48:S32–S40
  151. Kruskall MS, AuBuchon JP, Anthony KY, et al.  Transfusion to blood group A and O patients of group B RBCs that have been enzymatically converted to group O. Transfusion. 2000;40:1290–1298
  152. Garratty G. Stealth erythrocytes—A possible transfusion product for the new century?. Vox Sang. 2000;78:143–147

☆ This document represents the work of individuals and is not an official document of the National Blood Safety Council or the Quebec Public Health Institute.

☆☆ Funded by an unrestricted educational grant from the Hemosol Corporation.

★ Address reprint requests to Steven Kleinman, MD, 1281 Rockcrest Avenue, Victoria, BC, V9A-4W4 Canada.

★★ 0887-7963/03/1702-0004$30.00/0

PII: S0887-7963(03)90003-4

doi: 10.1016/S0887-7963(03)90003-4

Transfusion Medicine Reviews
Volume 17, Issue 2 , Pages 120-162 , April 2003

Article Tools